Australia's most trusted
source of pharma news
Posted 22 April 2026 PM
Novotech has been given the go-ahead by the Office of the Gene Technology Regulator (OGTR) to conduct a clinical trial of Akamis Bio’s lead oncolytic immunotherapy NG-350A in Australian patients with locally advanced rectal cancer.
The Phase 1b study aims to administer NG-350A intravenously, in combination with chemoradiotherapy, in up to 40 adults aged 18 and over with locally advanced rectal cancer and at least one risk factor for local or distant recurrence at clinical trial sites and hospitals in Australia.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.